Trade Cyclerion Therapeutics, Inc. - CYCN CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.0544 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023318% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001096% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 0.01 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 2.8928 |
| Open | 2.8128 |
| 1-Year Change | 2.6% |
| Day's Range | 2.8128 - 2.9928 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 24, 2025 | 2.9928 | 0.1000 | 3.46% | 2.8928 | 2.9928 | 2.8128 |
| Apr 23, 2025 | 2.8928 | 0.2200 | 8.23% | 2.6728 | 2.9428 | 2.6728 |
| Apr 22, 2025 | 2.9328 | 0.2400 | 8.91% | 2.6928 | 2.9328 | 2.5828 |
| Apr 21, 2025 | 2.6928 | 0.0600 | 2.28% | 2.6328 | 2.7228 | 2.5628 |
| Apr 17, 2025 | 2.6728 | 0.0400 | 1.52% | 2.6328 | 2.6828 | 2.5628 |
| Apr 16, 2025 | 2.6728 | 0.0500 | 1.91% | 2.6228 | 2.6728 | 2.5828 |
| Apr 15, 2025 | 2.6928 | 0.0800 | 3.06% | 2.6128 | 2.6928 | 2.6128 |
| Apr 14, 2025 | 2.7628 | 0.2700 | 10.83% | 2.4928 | 2.8928 | 2.4028 |
| Apr 11, 2025 | 2.5528 | 0.0500 | 2.00% | 2.5028 | 2.5528 | 2.4628 |
| Apr 10, 2025 | 2.5528 | 0.1500 | 6.24% | 2.4028 | 2.5528 | 2.3928 |
| Apr 9, 2025 | 2.5128 | 0.1100 | 4.58% | 2.4028 | 2.5128 | 2.3928 |
| Apr 8, 2025 | 2.5928 | 0.1300 | 5.28% | 2.4628 | 2.6428 | 2.4628 |
| Apr 7, 2025 | 2.4628 | 0.0700 | 2.93% | 2.3928 | 2.5428 | 2.3928 |
| Apr 4, 2025 | 2.4928 | 0.1000 | 4.18% | 2.3928 | 2.5428 | 2.3728 |
| Apr 3, 2025 | 2.4928 | -0.1000 | -3.86% | 2.5928 | 2.6228 | 2.4428 |
| Apr 2, 2025 | 2.5928 | 0.0600 | 2.37% | 2.5328 | 2.6928 | 2.4828 |
| Apr 1, 2025 | 2.5228 | 0.0300 | 1.20% | 2.4928 | 2.5828 | 2.4928 |
| Mar 31, 2025 | 2.4128 | -0.0600 | -2.43% | 2.4728 | 2.4928 | 2.3928 |
| Mar 28, 2025 | 2.4928 | -0.0100 | -0.40% | 2.5028 | 2.5128 | 2.4228 |
| Mar 27, 2025 | 2.5028 | 0.0000 | 0.00% | 2.5028 | 2.5128 | 2.4328 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Cyclerion Therapeutics, Inc. Company profile
About Cyclerion Therapeutics Inc
Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company's lead asset, CY6463, is a central nervous system (CNS)-penetrant, soluble guanylate cyclase (sGC) stimulator that is in clinical development for Alzheimer's disease with vascular pathology (ADv), cognitive impairment associated with schizophrenia (CIAS), and mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS). CY6463 is an orally administered CNS-penetrant sGC stimulator that is being developed as a symptomatic and disease-modifying therapy for serious CNS diseases. Its CNS asset, CY3018, is a differentiated CNS-penetrant sGC stimulator with CSF-to-plasma exposure relative to CY6463. CY3018 is focused on sGC stimulation for the treatment of disorders of the CNS. Its non-CNS assets include Praliciguat and Olinciguat. Praliciguat is an orally administered, once-daily systemic sGC stimulator. Olinciguat is an orally administered, once-daily, vascular sGC stimulator.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Cyclerion Therapeutics Inc revenues increased 72% to $3.9M. Net loss decreased 34% to $51.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Research & Development - Balancing value decrease of 32% to $33.7M (expense), General & Administrative - Balancing decrease of 27% to $15M (expense).
| Industry: | Biotechnology & Medical Research (NEC) |
301 Binney Street
CAMBRIDGE
MASSACHUSETTS 02142
US
News
ECB interest-rate forecasts – Projections for the next five years
The European Central Bank (ECB) plays a pivotal role in the economic stability of the eurozone, meaning ECB interest-rate forecasts are key to understanding how financial and economic scenarios might evolve.
14:37, 10 April 2025
BlackRock shareholders: Who owns the most BLK stock?
BlackRock is the leading asset manager in the world – but who are its biggest shareholders? Read on to find out.
13:46, 9 April 2025
Bitcoin price predictions 2025–2050: third-party price target
We examine bitcoin price predictions for 2025 and beyond, with insights from third-party analysts and market experts.
10:28, 9 April 2025
Tesla (TSLA) stock forecast 2025 and beyond: third-party Tesla price target
Where will Tesla’s stock be in five years? Can the EV company keep its crown?
08:19, 9 April 2025
JasmyCoin price predictions 2025-2030: Third-party price target
How might JASMY behave in the future?
16:13, 8 April 2025
Australian interest-rate projections: where will rates be in 5 years?
As one of the most closely watched economic indicators, Australian interest-rate projections offer valuable insight into the future of the country’s economy.
21:37, 7 April 2025
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025People also watch
Still looking for a broker you can trust?
Join the 720,000+ traders worldwide that chose to trade with Capital.com